Mahamaya Lifesciences Ltd IPO

LISTED

SME

NSE • Lot Size: 1200 • Fertilizers

Issue₹114

→

Listed₹116+2%

→

Now₹191+67.5%

↑67.5%

*Last updated on 11 Jan 2026

Price Band

₹108 - ₹114

Lot Size

1200

Issue Size

₹70.44 Cr

GMP

N/A

Subscription

1.63x

Analyzing...

IPO Schedule

Open

11 Nov 2025

13 Nov 2025

Allotment

14 Nov 2025

Listing

18 Nov 2025

About Mahamaya Lifesciences Ltd

Mahamaya Lifesciences Ltd. is an Indian pharmaceutical company focused on manufacturing and marketing generic pharmaceutical products. They operate primarily in the domestic market, catering to various therapeutic segments.

Key Strengths

Strong Return on Equity (ROE) of 34.94% indicates efficient utilization of shareholder funds.
Relatively low Price-to-Earnings (P/E) ratio of 15.65 suggests a potentially undervalued offering compared to industry peers (further benchmarking required).
Focus on generic pharmaceuticals allows for cost-effective manufacturing and wider market reach.
Established presence in the domestic market provides a stable revenue stream.
SME segment listing provides growth opportunities through enhanced visibility and capital access.

Risk Factors

•SME IPOs are inherently more volatile than mainboard IPOs.
•Dependence on the domestic market exposes the company to regulatory changes and competitive pressures within India's pharmaceutical sector.
•The generic pharmaceutical industry is highly competitive, requiring constant innovation and cost management.

Valuation Analysis

The IPO appears reasonably priced considering the ROE and P/E ratio, but investors should conduct thorough due diligence and compare the valuation with similar companies in the SME pharmaceutical segment to ascertain its attractiveness.